A subset of people infected with human immunodeficiency virus type 1 (HIV-1), called 'elite controllers' here, are distinguished by their ability to maintain a state of apparently durable control of HIV-1 replication without the need for antiviral therapy 1, 2 . Viral control is linked to the expression of certain alleles encoding human leukocyte antigen (HLA) class I molecules [3] [4] [5] , particularly HLA-B*57, HLA-B*27 and HLA-B*5801, which suggests an immunological basis related to the function of CD8 + T cells. A published genome-wide association study has indicated that the nature of the HLA-viral peptide interaction is the main factor that modulates durable control of infection with HIV-1 in the absence of antiretroviral therapy 6 . However, the mechanistic basis for the association remains unclear, and it is also unclear why most people with so-called 'protective HLA alleles' actually develop progressive disease.
Many studies have attempted to define quantitative and qualitative differences in CD8 + T cell responses that may be associated with different outcomes in terms of control of viremia by the immune response. Simple quantitative measures have shown little correlation with viral control 7, 8 , which suggests that qualitative features of CD8 + T cells may modulate efficacy. Factors that potentially modulate protective HLA-associated CD8 + T cell responses include, among others, polyfunctionality 9 , antigen sensitivity or functional avidity 10, 11 , proliferative capacity 12 , loading of lytic granules 13 , ex vivo expression of perforin 14 , specific targeting of conserved viral regions 15, 16 , immunoregulatory mechanisms [17] [18] [19] , concurrent responses to multiple viral epitopes restricted by different HLA alleles 20 , CD8 + T cell-associated mutations that impair viral fitness 21, 22 and escape from the immune response 23 . Many studies have also suggested that properties of the interaction among the T cell antigen receptor (TCR), viral peptide and major histocompatibility complex may be involved 24, 25 . However, the extent to which any of these factors influences the antiviral efficacy of the human immune response, as reflected by in vivo viral load, remains unclear, in part because of a lack of direct comparison of viral epitope-specific CD8 + T cell responses in people able to control infection with HIV-1 (controllers) and those who progress to disease after infection with HIV-1 (progressors), sequence diversity in epitopes of HIV-1 targeted by the immune system that leads to escape from the immune response, and the potential confounding effect of the targeting of multiple epitopes via diverse HLA molecules.
To address those limitations, we focused on HIV-1-infected people who express HLA-B*2705, which represents a situation in which the immune response is mostly if not exclusively mediated by targeting of a single epitope, KK10, of the group-associated antigen (Gag) protein p24 (sequence, KRWIILGLNK; amino acids 263-272) 23 . From a large, well-pedigreed cohort 26 , we specifically selected five controllers and five progressors who express HLA-B*2705 for whom the dominance of single clonotypes in each person, we did not observe 'preferential' use of a particular complementarity-determining region 3 (CDR3) motif among the various KK10-specific CD8 + T cell clonotypes (Table 1) . Indeed, of the clonotypes identified, only two clonotypes were the same in two different people (subjects CTR22 and CR420 had the same clonotype (TCRBV27TCRBJ1-1) and CDR3 sequence (CASSGGRRAF); and subjects CTR22 and CR540 had the same clonotype (TCRBV21TCRBJ2-7) and CDR3 sequence (CASTNRGSEQY)), and only one subject (CR420) had a TCRBV4-3TCRBJ1-3 clonotype similar to that reported before in people who express HLA-B*27 in whom viral loads vary between 1,880 and 202,590 RNA copies per milliliter of plasma 28, 30, 31 . These data indicated that KK10-specific CD8 + T cells were quantitatively similar but demonstrated considerable heterogeneity in TCR use among people who targeted a genetically identical epitope through a genetically identical HLA allele, in whom we observed considerable differences in viral load.
Functional characteristics of KK10-specific T cells
Many reports have suggested qualitative features of CD8 + T cells associated with viral control. One such measure is antigen sensitivity (often called 'functional avidity') 10, 11, 31 , and HLA-B*27 is characterized by T cell responses of high sensitivity 28 . However, whether antigen sensitivity varies with viral load in people who express HLA-B*27 and contain virus with the wild-type epitope has not been determined, to our knowledge. We next assessed antigen sensitivity in each of our subjects by examining (by ELISPOT) IFN-γ responses at limiting concentrations of KK10. There was no difference between controllers and progressors in the sensitizing dose of peptides needed to yield 50% maximal effector-cell triggering of IFN-γ production by peripheral blood mononuclear cells (PBMCs; Fig. 2a ). These results, in which all responses were detected in the presence of wild-type KK10 and therefore were not confounded by potentially cross-reactive responses induced by substitutions in the epitope sequence, were consistent with published reports showing that most clones specific for KK10 have similar antigen sensitivity 10 .
We next examined polyfunctionality ex vivo, including the ability of HLA-B*2705-restricted, KK10-specific CD8 + T cells to simultaneously produce the effector cytokines and chemokines IFN-γ, interleukin 2 (IL-2), tumor necrosis factor and CCL4 (MIP-1β) and to release cytotoxic factors by monitoring expression of the degranulation marker CD107a after stimulation with KK10. Published population studies have shown that the ability of CD8 + T cells to produce four or five cytokines and chemokines concurrently is associated with HIV-1 controllers 9 , and although some epitope-specific responses have been evaluated in this manner 10, 28, 32 , to our knowledge this has not been examined for HLA-B*27-restricted responses in people known to have the wild-type virus, in whom the inducing antigen is thus the same. When we did this analysis for the KK10 epitope (Fig. 2b) , cells that secreted CCL4 (MIP-1β) dominated the response in both progressors and controllers, consistent with published findings 9 . Pairwise comparisons showed several subsets in the two groups with significantly different functional profiles. For example, cells with dual expression of both IFN-γ and CCL4 (MIP-1β) were of significantly greater frequency in controllers, whereas cells with dual expression of both IFN-γ and tumor necrosis factor were of significantly greater frequency in progressors (Fig. 2b) . However, although controllers showed enrichment for cells with expression of more than three cytokines and chemokines, this did not reach statistical significance (P = 0.1) and these cells made up only a small subset of the total KK10-specific CD8 + T cell response.
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Published studies have shown that chronic infection with HIV-1 skews the maturation of HIV-1-specific CD8 + T cells toward development into preterminally differentiated cells with poor cytotoxic activity 33 . We stained peripheral blood cells for CD27 and CD45RA as described 34 to phenotypically distinguish four distinct subpopulations of KK10-specific cells. We detected similar proportions of KK10-specific cells with a central memory phenotype (KK10 + CD27 + CD45RA − ), effector memory phenotype (KK10 + CD27 − CD45RA − ) or terminally differentiated effector memory phenotype (KK10 + CD27 − CD45RA + ) in the controllers and progressors (Supplementary Fig. 1) . Moreover, we observed that HIV-1-infected GXR cells (a green fluorescent protein (GFP) reporter T cell line, derived from the human lymphoblastoid CD4 + T cell line CEM, that fluoresces green after infection with HIV-1) expressing HLA-B*2705 (refs. 35,36) stimulated the proliferation of KK10-specific cells to a similar degree in both groups (Fig. 2c,d ). Together these data indicated that the superior control of wild-type viremia in these elite controllers relative to that in chronic progressors expressing HLA-B*27, all of whom were treatment naive, 
Neutralization of virus by KK10-specific T cells
Having shown that the measures of responses to the immunodominant KK10 Gag epitope noted above did not differentiate controllers from progressors, we next evaluated the functional ability of responses to this epitope to inhibit HIV-1 replication in vitro 37 . We limited our initial analysis to the elite controllers, in whom outgrowth of autologous virus in CD4 + T cells is delayed considerably 38 , which allowed us to use controlled inocula of exogenous HIV-1 isolates to infect these cells and measure the ability of defined numbers of CD8 + T cells to inhibit viral replication. We included in this analysis all five HLA-B*2705 + elite controllers demonstrated to have wildtype KK-10 epitope sequences in virus in their plasma and provirus in their PBMCs ( Table 1) and assessed the antiviral ability of bulk CD8 + T cells and CD8 + T cell samples depleted of KK10-specific cells to inhibit viral replication in autologous CD4 + T cells by measuring the production of p24 antigen in the supernatant over 7 d (ref. 35 ). The addition of bulk CD8 + T cells to HIV-1-infected CD4 + T cells resulted in three to four logs less production of p24 antigen at day 7 in culture, whereas viral inhibition was over 90% less after the addition of cell samples from which KK10-specific CD8 + T cells were depleted (Fig. 3a) . This confirmed that the main immune control was mediated by the KK10-specific response in each of these subjects and showed that all of the HLA-B*27 + controllers were able to limit viral replication in vitro.
We next sought to assess the antiviral function of CD8 + T cells from the progressors. However, outgrowth of autologous virus in HIV-1 progressors complicated the virus-inhibition assay when we used autologous CD4 + T cells as target cells (data not shown). We therefore sought to confirm the utility of an assay based on the use of GXR cells encoding HLA-B*2705 as target cells 35, 36 . When we used those target cells together with bulk CD8 + T cells from controllers, we noted considerable inhibition of replication; moreover, there was nearly complete loss of viral inhibition after depletion of KK10-specific cells from bulk CD8 + T cell populations (Fig. 3b) . In contrast, we observed no viral inhibition by bulk CD8 + T cells from HIV-1 − people in the presence of HIV-1-infected autologous CD4 + T cells or HLA-B*2705-expressing GXR cells. In addition, we observed no inhibition by bulk CD8 + T cells from controllers in the presence of HLA-B*2705 − GXR cells after infection with the same virus (data not shown). 
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Having shown that this assay provided evidence of active viral neutralization by ex vivo KK10-specific CD8 + T cells in HLA-B*2705 + elite controllers and that this assay was sensitive to KK10 epitope specificity and HLA-B*2705 expression, we next evaluated CD8 + T cells from the progressors. Infected GXR cells expressing HLA-B*2705 were inhibited by the addition of CD8 + T cells from progressors ( Fig. 3c ), but to a much smaller degree than had been noted with cells from controllers. We obtained this result despite the finding of no quantitative differences in KK10-specific cells in controllers and progressors, as shown by tetramer staining and ELISPOT assay for IFN-γ (Fig. 1) .
We next extended the studies reported above to determine the ability of KK10-specific CD8 + T cell responses in controllers and progressors to recognize viral variants known to arise in vivo that are able to escape the immune response 36 . Computational studies have suggested that protective HLA alleles are associated with enhanced cross-reactivity 25 , but this has not been evaluated, to our knowledge, in the context of a single allele encoding HLA class I and single viral epitope in a comparison of controllers and progressors. For this, we analyzed by flow cytometry the recognition of wild-type HIV-1 and viral variants by KK10-specific CD8 + T cells among bulk CD8 + T cells from controllers and progressors. We evaluated the proportion of GFP + cells after infecting HLA-B*2705-expressing GXR cells. We again used the GXR cell assay system rather than autologous CD4 + T cells to overcome the problem of outgrowth of autologous virus from the chronic progressors and avoid potential variability of CD4 + T cell responses among study subjects.
We assessed the recognition of HIV-1 strain NL4-3 with the wildtype KK10 epitope, as well as HIV-1 NL4-3 variants with mutant KK10 sequences ( Table 2) , by KK10-specific CD8 + T cells from elite controllers and chronic progressors (results for HLA-B*2705 + elite controller FW56 and chronic progressor CR540, Fig. 4a ). We found essentially complete inhibition of the replication of wild-type HIV-1 NL4-3 and broad recognition of viral variants by KK10-specific CD8 + T cells from controller FW56, as well as considerable inhibition of the typical early L6M mutant virus, which we did not detect in this subject. In contrast, inhibition of both of these targets by CD8 + T cells from progressor CR540 was present but minimal. Although peak infection with the other mutant viruses was less than that noted with wild-type virus or the L6M mutant virus, CD8 + T cells from controller FW56 inhibited all variants, whereas CD8 + T cells from progressor CR540 were ineffective, even though both subjects had similar proportions of KK10-specific effector cells, as quantified by tetramer staining (Table 1) , and proliferative capacity in response to HIV-1-infected, HLA-B*2705-expressing GXR cells (Fig. 2c) . We consistently observed the superiority of HIV-1-specific CD8 + T cells from elite controllers in antiviral efficacy against wild-type HIV-1 NL4-3 and viral variants when we extended these detailed studies to all the elite controllers and chronic progressors (Fig. 4b) . In addition, bulk CD8 + T cells from HIV-1 − people (which included HLA-B*2705 + donors) did not inhibit viral replication in HLA-B*2705-expressing GXR cells (Fig. 4b) . We obtained similar results in terms of killing efficacy against the same HIV-1-infected, HLA-B*2705-expressing GXR cells by standard chromium-release assays of cells from the controllers and progressors (Fig. 4c) .
Together these data indicated a clear distinction between elite controllers and chronic progressors in HLA-B*2705-restricted CD8 + T cells targeting the KK10 epitope based on the potency and epitope. In addition, we found that the CDR3 sequences of KK10-specific clonotypes were significantly closer to germline sequences in controllers than in progressors (P = 0.001; Supplementary Fig. 2) , which would confer a greater ability to recognize epitope variants 39 . These functional data were also consistent with computational modeling showing that thymic selection in the context of protective HLA alleles is more likely to generate a cross-reactive CD8 + T cell repertoire that targets mutant viral epitopes, thereby contributing to improved control of a highly variable pathogen 25 .
Antiviral efficacy of KK10-specific clonotypes
The data reported above indicated that there were differences between controllers and progressors in the potency and crossreactivity of recognition of wild-type HIV-1 and viral variants in the KK10-specific CD8 + T cell responses, which suggested that the fine specificity of the TCR might be modulating these effects. Given that we had observed different clonotypes in the tetramerpositive populations in these subjects (Table 1) , we next sought to determine clonotypic antiviral efficacy. We therefore cloned KK10-specific CD8 + T cells by limiting dilution from the sorted KK10 tetramer-positive cells from three elite controllers (CTR203, FW56 and CTR40) and two chronic progressors (CR540 and CR420) and then determined clonotypes by TCR sequencing ( Table 3 ). In each of these people, we cloned the dominant clonotypes identified in vivo, and in three of the five, we were able to generate multiple clones.
We assessed the ability of the clonotypic KK10-specific CD8 + T cells to kill HIV-infected target cells in a standard chromiumrelease assay and assessed their ability to inhibit viral replication, again using the HLA-B*2705-expressing GXR cells. For controller CTR203, we were able to establish clones representing five of the six clonotypes detected in peripheral blood. We observed considerable variation in the ability of these clonotypes to recognize HIV-1 and viral variants (Fig. 5) that ranged from broad recognition of the variants by the two most dominant CTR203 clonotypes to weak and narrow recognition by all three subdominant CTR203 TCR variants. Extending this to clones from five subjects, we found that the most effective clonotypes were the immunodominant in vivo clonotypes from the controllers, including the two codominant responses in subject CTR203, the two codominant responses in subject FW56 and the one dominant response in subject CTR40. These were significantly more potent at viral recognition than were the immunodominant clones from the progressors. We observed codominant npg clonotype TCRBV4-3 in controller FW56, which showed efficient recognition of wild-type virus and had less robust activity than codominant FW56 clonotype TCRBV6-5 had against the L6M variant and was unable to recognize any of the other variants, at a low frequency in progressors CR540, CR420 and 8222 in the context of different sequences of CDR3 or joining segments. Subdominant clonotypes from the elite controllers included CRBV27TCRBJ2-2, TCRBV20-1TCRBJ2-7 and TCRBV20-1TCRBJ1-2, all of which were associated with inferior recognition of wild-type virus and the L6M variant and showed the least efficacy against the other viral variants. However, these less-effective clonotypes were dominantly selected by progressors CR338, 8222 and CR420. They were rearranged with variant CDR3 or joining segments but were likewise less efficient at recognizing HIV-1-infected cells. Moreover, none of the subdominant clonotypes, whether from controllers or progressors, were able to efficiently recognize HIV-1-infected cells or to inhibit viral replication. We obtained consistent results in terms of the ability of individual clonotypes to inhibit viral replication (Supplementary Fig. 3 ). Together these data indicated that differences in the antiviral efficacy of KK10-specific CD8 + T cells in HIV-1-infected people were defined by the dominance of clonotypes that conferred distinct antiviral potential on CD8 + T cells.
Antiviral efficacy of TW10-specific clonotypes
We further examined the effect of individual TCR clonotypes on antiviral efficacy with HLA-B*5701-restricted CD8 + T cell clones specific for the epitope TW10 of Gag in a chromium-release assay with HIV-1-infected, HLA-B*5701-expressing GXR cells (Fig. 6) . We generated HLA-B*5701-restricted TW10-specific CD8 + T cell clones by limiting dilution of cells sorted from HLA-B*57 + elite controllers (CTR53 and CR462) and a chronic progressor (CR555) through the use of an HLA-B*57-TW10 tetramer and then clonotypically assessed these by TCR sequencing. Again, we observed that variant clonotypes had differences in antiviral efficacy and that, overall, clones from the elite controllers were more potent and cross-reactive in recognition of HIV-1 and viral variants than were clones from the progressor (Fig. 6) . Together these data indicated that the difference between the controllers and progressors of the same epitope-specific CD8 + T cell responses in the recognition of HIV-1 and viral variants was related to distinct TCR clonotypes selected during natural infection.
Lytic granule loading and delivery by clonotypes
The data reported above indicated clonotype-specific differences in antiviral function, which offered the opportunity to define the A r t i c l e s mechanisms that account for these phenotypes. We next determined the effect of TCR clonotype on the loading of lytic granules after recognition of HIV-1-infected target cells and the ability of clonotypespecific T cells to deliver perforin to infected target cells. We measured by flow cytometry the expression of perforin and granzyme B by various clonotypes 12, 13 . After culture for 3 d with KK10-specific, HLA-B*2705-expressing GXR cells infected with wild-type HIV-1, dominant clonotypes from controllers had efficient expression of perforin. In contrast, subdominant clonotypes from controllers and all the clonotypes from progressors were significantly less efficient at expressing perforin than were dominant clonotypes from controllers (Fig. 7a) . We obtained similar results for the expression of granzyme B (P < 0.0001; Supplementary Fig. 4) .
We also examined by confocal microscopy effector cell-target cell conjugation and the loading and delivery of granules 40 . After incubation for 30 min with HIV-infected, HLA-B*2705-expressing GXR cells, more perforin was polarized to synapses and released into target cells for the inhibitory clonotypes than for the noninhibitory clonotypes (Fig. 7b) . Extended quantitative analysis of perforin loading and delivery showed that significantly less perforin was delivered to synapses ( Fig. 7c) and released into target cells (Fig. 7d) by subdominant clonotypes from controllers and all the clonotypes from progressors than by dominant clonotypes from controllers. As a control, we confirmed that endogenous perforin was undetectable in HIV-1-infected GXR cells ( Supplementary  Fig. 5 ). We observed similar basal amounts of perforin in inhibitory and noninhibitory clonotypes without stimulation of target cells (P = 0.96; Supplementary Fig. 6 ), which indicated that the functionally effective clones rapidly upregulated perforin loading after the recognition of cognate antigens. These data indicated that TCR clonotypes associated with enhanced ability to inhibit HIV-1 replication did so by rapidly upregulating lytic granules at immunological synapses after engagement of a target cell and delivery of these granules into the infected cell.
DISCUSSION
Alleles encoding certain HLA-B types are associated with enhanced control of viremia in HIV-1-infected people [3] [4] [5] , and this effect maps to specific host amino acids in the HLA-B peptide-binding groove 6 . However, most people with such so-called 'protective alleles' , such as those encoding HLA HLA-B*27 and HLA-B*57, experience progressive infection 26 . To address the basis of these differences in outcome, we compared CD8 + T cell responses to immunodominant viral epitopes in treatment-naive elite controllers and chronic progressors. To limit the number of potential confounding variables, we studied only subjects with wild-type sequences of the respective T cell epitopes in the virus in their plasma and provirus in their PBMCs and with the same HLA class I-restricting allele. In this setting, in which contemporaneous escape from the immune response is not a confounding issue, we found that CD8 + T cell responses by HIV-1 controllers were more potent at inhibiting HIV-1 replication than were those of progressors that targeted the same epitopes and were better able to 'cross-recognize' HIV-1 viral variants that typically arise in vivo. Moreover, these effects were associated with a unique ability of the dominant TCR clonotypes to upregulate perforin and granzyme B, which provides a mechanistic explanation for the divergent disease outcomes in people with protective HLA alleles.
Many characteristics of CD8 + T cells have been reported to be associated with enhanced control of viremia, including differences in polyfunctionality, proliferative capacity and functional avidity of KK10-specific CD8 + T cells. In the carefully controlled comparative studies done here of a small cohort of well-pedigreed controllers and progressors expressing protective alleles, none of those reported associations reached statistical significance. In contrast, the ability of both bulk CD8 + T cells as well as epitope-specific TCR clonotypes to inhibit viral replication, cross-recognize viral variants and upregulate perforin and granzyme B, which are probably the most important in vivo functions of these cells, was highly significant. Overall, our study has linked the antiviral efficacy of the two most protective HLA class I molecules to CD8 + T cell clonotypes selected during natural infection with HIV-1 and has demonstrated that TCR rearrangement modulated the effect of protective alleles on disease outcome.
Our study is distinct from other reports of TCR clonotype use by KK10-specific CD8 + T cells in people who express HLA-B*27 in that we selected the subjects by 'extremes' of viral load. As noted in other published studies 28, 29 , we observed considerable diversity in clonotype recruitment and CDR3 motifs in KK10-specific CD8 + T cell populations, as well as a dominance of clonotypes in progressors who were unable to cross-recognize the L6M mutant. The mutation that results in this mutant is known to occur early during the course of HIV-1 infection with little or no effect on peptide processing 27 , binding of peptide to HLA-B*27 (ref. 27) recognition by the TCR 41 or viral fitness 36 , but it is an important intermediate mutation on the path to complete escape of the immune response. Although we detected such ineffective responses at the clonal level in both controllers and progressors in our cohort, HLA-B*27 + elite controllers had dominant clonotypes that targeted not only the L6M mutant but also other mutants, including substitution at position 2 of KK10 alone or in combination with the L6M substitution, which diminishes the binding of peptide to HLA-B*27 and impairs viral replication 36 . Thus, the TCR clonotypes in controllers comprised effective and ineffective clonotypes, whereas those in progressors were limited to lesseffective clonotypes.
In contrast to some other published reports 42, 43 , we found no significant difference between the two groups in the use of 'public' clonotypes (defined as those that expressed identical TCR β-chain amino acid sequences and recurred in many people), despite significant differences in plasma viremia and the fact that 'public' clonotypes do not seem to dominate among controllers 29 . However, controllers used TCR β-chain clonotypes with sequences encoding CDR3 that were significantly more 'germline-like' than those used by the progressors. The lower number of nucleotide additions in the germline-like genes encoding CDR3 is a hallmark of clonotypes found at high frequency in naive and memory T cell pools and also shared by many people 44 . The mechanism underlying this advantage bestowed by germlinelike genes encoding CDR3 may be related to higher precursor frequency and/or greater ability to recognize mutational variants of the epitope 39, 42 . Furthermore, the most effective clonotypes, in terms of viral inhibition and cytotoxic recognition of wild-type and variant viruses, were dominantly selected in vivo by the controllers but were either absent or subdominantly selected in KK10-specific CD8 + T cell populations of the progressors. In contrast, the clonotypes associated with inferior recognition of wild-type virus and the least efficacy against the viral variants were dominantly selected by the progressors but subdominantly selected by the controllers.
Although our study has clearly shown that the TCR modulated the protective effect of HLA molecules, it has many limitations. Our HLA-B*2705 studies were limited to only five controllers and five progressors, and many published reported associations with viral control did not reach statistical significance in this small study group. Nevertheless, even with these small numbers, the results showing that npg TCR clonotypes modulated the protective effect of HLA-B were of high statistical significance in demonstrating greater cytotoxic killing and greater cross-reactivity by the dominant clonotypes in controllers than by those in progressors. We were not able to generate CD8 + T cell clones that represented all detectable TCR clonotypes in all people, but in one subject we were able to test five of six clonotypes in vivo that represented 90% of the detectable TCR diversity in that subject. Moreover, all controllers evaluated at the clonal level had dominant TCR clonotypes that were highly effective, whereas these were absent in both dominant and subdominant clones established in the progressors. Of note, the important role of TCR clonotypes in distinguishing viral control from lack of viral control was probably mediated by direct cytotoxicity of HIV-1-infected cells, with perforin upregulation noted within 30 min of recognition of the cognate epitope and not requiring proliferation of CD8 + T cells. The data presented here contrast with the well-documented differences between nonprogressors and progressors in the proliferative capacity of CD8 + T cells 12 , probably because of the way proliferation was measured. In our study here, we used HIV-1-infected GXR cells expressing HLA-B*2705 as stimulator cells in culture with bulk CD8 + T cells and observed similar proliferative capacity for HLA-B*27 + KK10-specific CD8 + T cells from controllers and progressors. This could be explained by the similar abundance of CD4 + T cells in the progressors and controllers, the properties of regulatory T cells in people who express alleles encoding protective HLA molecules 17 or compensation for in vivo impaired CD4 + helper T cell function in progressors by cytokines produced by the cell line used for stimulation. Finally, whether our results can be extrapolated to other protective alleles and other epitopes will require additional study.
Together our data have indicated that TCR use modulates virusinhibitory capacity and recognition of naturally arising HIV-1 variants and thus modulates the effect of protective HLA alleles. Our data have suggested that TCR clonotypes that inhibit viral replication and confer cross-recognition of viral epitope variants that can eventually arise in vivo may be critical to long-term control of viremia. Efforts to define the factors that contribute to junctional rearrangement of more effective TCRs may be of critical importance for the design of T cell vaccines and therapeutic strategies for highly variable pathogens such as HIV-1.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Study subjects. PBMCs and plasma samples from HIV-1-infected people and HIV-1 − people were used in this study according to protocols approved by the Institutional Review Board of the Massachusetts General Hospital. Elite controllers were defined as having a concentration of HIV-1 RNA below the limit of detection for the assay used (for example, <75 RNA copies per ml by branched DNA assay, or <50 copies by ultrasenstive PCR), without antiretroviral therapy. Treatment-naive chronic progressors in the study had a median viral load of 12,833 copies per ml (range, 4,073-22,094 copies per ml). CD4 + T cell counts, viral loads and HLA types were determined as described 26 (characteristics of study subjects, Table 1 ).
Viruses and synthetic peptides. The chemokine receptor CXCR4-tropic HIV-1 laboratory strain NL4-3 was obtained from the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health. HIV-1 laboratory strain NL4-3 was also modified to express one or more mutations in the gene encoding Gag p24 as described 36, 45 . Peptides corresponding to described optimal HIV-1 epitopes and their variants were synthesized at the Massachusetts General Hospital Peptide Core Facility on an automated peptide synthesizer by fluorenylmethoxycarbonyl technology.
Virus sequencing. Nested PCR for viral DNA or RNA was done as described 46 . PCR fragments were sequenced by population for the identification of regions of sequence variation. All fragments were sequenced bidirectionally on an ABI 3730xl automated sequencer (Applied Biosystems).
ELISPOT assay. IFN-γ was measured by ELISPOT assay as described, with optimally defined epitopes and designated concentrations of peptide 8 . The density of input cells ranged from 1 × 10 4 cells per well to 1 × 10 5 cells per well. For the quantification of specific spot-forming cells, the number of spots in the negative-control wells was subtracted from the number of spots in each experimental well. Responses were considered positive if they had at least three times the mean number of spot-forming cells in the three negative-control wells; positive responses also had to achieve a value of least 50 spot-forming cells per 1 × 10 6 PBMCs. The magnitude of the epitope-specific response is presented as spot-forming cells per 1 × 10 6 cells.
Generation of CD8 + T cell clones. PBMCs were stained with fluorophoreconjugated HLA tetramer refolded with epitopic HIV-1 peptides (Beckman Coulter) and fluorophore-labeled antibody to CD8 (anti-CD8; RPA-T8; BD) and anti-CD3 (UCHT1; BD). Tetramer-positive CD8 + cells were sorted on a FACSAria (BD Biosciences) at 70 p.s.i., and single cells were placed into each well of 96-well plates, with irradiated allogeneic PBMCs and monoclonal antibody 12F6 to CD3 (a gift from J. Wong) as a stimulus for T cell proliferation 47 . Developing epitope-specific clones were further tested by ELISPOT assay of IFN-γ with optimal epitopes and with tetramer staining. Cloned CD8 + T cells were maintained by restimulation every 14-21 d with monoclonal anti-CD3 and irradiated allogeneic PBMCs in RPMI-1640 medium containing 50 U/ml of recombinant IL-2, as described 47 .
Sequencing of TCR a-and b-chains. Tetramer-positive CD8 + cells were sorted from PBMCs or cloned CD8 + T cells and mRNA was extracted with the RNeasy mini kit (Qiagen). Anchored RT-PCR was then done with a modified version of the SMART (switching mechanism at 5′ end of RNA transcript) procedure and a 3′-primer for the TCR α-or β-chain constant region (C α or C β ) to obtain PCR products containing the V α or V β chain in addition to the CDR3, the J α or J β region and the beginning of the C α or C β region. RT-PCR and sequencing and analysis of genes encoding TCR α-and β-chain were done as described 48 .
Tetramer staining. Cells were first stained for 15 min with blue viability dye (L-23105; Molecular Probes, Invitrogen), then were stained for 30 min at room temperature with allophycocyanin-or phycoerythrin-conjugated MHC class I tetramer folded with KK10 peptide (Beckman Coulter). Surfaces of cells were then stained with the following antibodies (all from BD Pharmingen): anti-human CD3 (UCHT1), anti-human CD8 (RPA-T8), anti-human CD14 (M5E2), anti-human CD19 (HIB19) and anti-human CD56 (B159). Samples were acquired on an LSRFortessa (BD Biosciences) and data were analyzed with FlowJo software (version 9.0.2).
Surface and intracellular staining. Cells (2 × 10 6 ) were stimulated for 1 h at 37 °C and 5% CO 2 with KK10 at a final concentration of 20 ng/ml. Phycoerythrin-indodicarbocyanine-conjugated anti-CD107a (H4A3; BD) was also added at the beginning of the stimulation period for analysis of degranulation. After 1 h, 10 ng/ml of brefeldin A (B7651; Sigma) was added and the cells were incubated for another 5 h. After stimulation, surfaces of cells were stained with the following antibodies: V500-anti-CD8 (RPA-T8; BD), allophycocyanin-indotricarbocyanine-anti-CD27 (MT271; BD) and Qdot 605-anti-CD45RA (H100; eBioscience). Cells were then fixed and permeabilized with Cytofix/Cytoperm solution (554722; BD) and stained with phycoerythrin-indotricarbocyanine-anti-IFN-γ (B27; BD), fluorescein isothiocyanate-anti-IL-2 (5344.111; BD), Alexa Fluor 700-anti-TNF (Mab11; BD), phycoerythrin-anti-MIP-1β (D21-1351; BD) and Qdot 655-anti-CD3 (S4.1; Invitrogen). Cells were acquired on an LSRFortessa (BD Biosciences) and data were analyzed with FlowJo software (TreeStar).
Proliferation assay. Primary CD8 + T cells were isolated from PBMCs by negative selection (Dynabeads; Invitrogen) with the proportion of CD3 + CD8 + T cells being >98%, as detected by flow cytometry. Cells were stained for 7 min at 37 °C with 0.35 µM CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes) and then were cultured for 7 d with medium alone or with HIV-1-infected or uninfected HLA-B*27-encoding GXR cells in RPMI-1640 medium in the absence of IL-2. After being labeled with the appropriate tetramer (Beckman Coulter), anti-CD8 (RPA-T8; BD) and anti-CD3 (UCHT1; BD), cells were fixed in 1% paraformaldehyde and analyzed on an LSRII (BD Biosciences).
Chromium release assay. HLA-B*27-or HLA-B*57-expressing GXR cells (which contain a plasmid encoding GFP driven by the long terminal repeat of HIV-1) were constructed as described 35, 36 and were infected with wildtype HIV-1 or viral variants at the appropriate multiplicity of infection. On day 5 after infection, viable virus-infected cells were sorted on a FACSAria (BD Biosciences) and labeled for 1 h at 37 °C with chromium. Bulk CD8 + T cells isolated from PBMCs by negative selection (Dynabeads; Invitrogen) or CD8 + T cell clones were then added at the appropriate effector cell/target cell ratio, and a standard 4-hour chromium-release assay was done as described 49 . Percent specific lysis was calculated as follows: [(mean experimental c.p.m. − mean spontaneous c.p.m.) / (mean maximum c.p.m. − mean spontaneous c.p.m.)] × 100. Spontaneous release or maximum release was determined by incubation of labeled target cells with medium alone or 2% Triton X-100, respectively.
Virus-inhibition assay. HLA-B*27-or HLA-B*57-expressing GXR cells were infected for 4 h at 37 °C with the appropriate HIV-1 strain or viral variant at the specified multiplicity of infection, then were washed and cultured together with bulk CD8 + T cells isolated from PBMCs by negative selection (Dynabeads; Invitrogen) or CD8 + T cell clones at the appropriate effector cell/target cell ratio. The ability to recognize HIV-1 and viral variants by CD8 + T cells was analyzed by flow cytometry as the proportion of GFP + cells over 7 d in culture. To additionally address the relative antiviral efficacy of epitopespecific CD8 + T cell responses, the ability of bulk CD8 + T cells and CD8 + T cell populations depleted of epitope-specific cells to inhibit viral replication in autologous primary CD4 + T cells was measured by analysis of p24 production as described 37 . Primary CD4 + T cells were isolated from PBMCs by negative selection (Dynabeads; Invitrogen). Over 98% of these primary cells coexpressed CD3 and CD4, as assessed by flow cytometry. Those CD4 + T cells were stimulated with monoclonal antibody bispecific for CD3 and CD8 (CD3:8; a gift from J. Wong) 50 and were infected for 4 h at 37 °C at day 3 with the appropriate HIV-1 isolates at a multiplicity of infection of 0.1, except as otherwise specified. Virus-infected cells were then washed and incubated in the presence or absence of effector cells at an effector cell/target cell ratio of 1:1 in RPMI-1640 medium in addition of IL-2 at 50 U/ml. At regular intervals, cultures were 'fed' by removal and replacement of one-half of the culture
